Drugs / Lumiracoxib
last change Nov 2012 re-read 2 minutes ago

Lumiracoxib

also known as COX189 · Prexige

Small molecule targets PTGS2 via inhibition

Developed for
osteoarthritis · osteoarthritis, knee · arthropathy · gout · hypertensive disorder · musculoskeletal system disorder · osteoarthritis, hip · rheumatoid arthritis
Investigated by
Novartis · Novartis Pharmaceuticals · Hospital Central Sur de Pemex

Trials 16 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01481610 Jan → Nov 2012 arthropathy, chronic renal failure syndrome Hospital Central Sur de Pemex Terminated No outcome recorded
Phase 38 trials
Phase 3 NCT00170872 Nov 2004 → Jul 2005 osteoarthritis, rheumatoid arthritis Novartis Completed No outcome recorded
Phase 3 NCT00154219 Nov 2004 → Oct 2006 osteoarthritis, hip Novartis Completed No outcome recorded
Phase 3 NCT00145301 Sep 2004 → Nov 2005 osteoarthritis Novartis Completed No outcome recorded
Phase 3 NCT00475800 Jan → Dec 2004 osteoarthritis, knee Novartis Completed No outcome recorded
Phase 3 NCT00476034 Dec 2003 → Nov 2004 osteoarthritis Novartis Completed No outcome recorded
Phase 3 NCT00367315 Sep 2003 → Feb 2004 osteoarthritis, knee Novartis Completed No outcome recorded
Phase 3 NCT00366938 Sep 2003 → Mar 2004 osteoarthritis, knee Novartis Completed No outcome recorded
Phase 3 NCT00267215 Nov 2000 → Feb 2001 osteoarthritis Novartis Completed No outcome recorded
Phase 47 trials
Phase 4 NCT00419796 Nov 2006 → Sep 2007 osteoarthritis Novartis Completed No outcome recorded
Phase 4 NCT00333567 Aug 2006 → ? Novartis Completed No outcome recorded
Phase 4 NCT00350155 May 2006 → ? Novartis Completed No outcome recorded
Phase 4 NCT00348491 Feb → May 2006 Novartis Pharmaceuticals Completed No outcome recorded
Phase 4 NCT00267176 Nov 2005 → Sep 2006 hypertensive disorder, osteoarthritis Novartis Pharmaceuticals Completed No outcome recorded
Phase 4 NCT00170781 Jun 2005 → ? gout Novartis Completed No outcome recorded
Phase 4 NCT00170898 Nov 2004 → ? musculoskeletal system disorder Novartis Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 20 sources stand behind the page.

FieldValueCited text
Known as Lumiracoxib ClinicalTrials.gov intervention name — accepted as the source's own label NCT00170898
15

NCT00145301

NCT00333567

NCT01481610

NCT00348491

NCT00419796

NCT00170781

NCT00476034

NCT00267215

NCT00475800

NCT00366938

NCT00267176

NCT00350155

NCT00154219

NCT00170872

NCT00367315

Known as COX189 “A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip...” NCT00154219
Known as Prexige “We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige) versus placebo and celecoxib in patients with knee osteoarthritis.” PMID 16469112 Jan 2006
Action Inhibit “lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor” PMID 18328090 Mar 2008
Modality Small molecule CHEMBL404108
Route Oral “lumiracoxib 100 mg once daily (o.d.) (n = 427), celecoxib 200 mg o.d. (n = 419), or matching placebo o.d. (n = 416) administered orally.” PMID 21607551 May 2011
Target PTGS2 “cyclo-oxygenase-2 selective inhibitor lumiracoxib” PMID 16469112 Jan 2006